Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Association between Lipoprotein(a) and Renal Function: Insights from a Cross-Sectional Study
Session:
SESSÃO DE POSTERS 36 - TUDO SOBRE LÍPIDOS
Speaker:
Samuel Azevedo
Congress:
CPC 2025
Topic:
J. Preventive Cardiology
Theme:
28. Risk Factors and Prevention
Subtheme:
28.14 Risk Factors and Prevention - Other
Session Type:
Cartazes
FP Number:
---
Authors:
Samuel Azevedo; Débora Silva Correia; Rita Barbosa Sousa; André Silva; André Jorge Garcia; Rui Gomes; Ana Rita Bello; Ana Catarina Ribeiro; Gonçalo Cunha; Marisa Trabulo; João Figueira; Jorge Ferreira
Abstract
<p style="text-align:start"><span style="font-size:12px"><span style="font-family:Arial,Helvetica,sans-serif"><span style="color:#000000"><strong>Introduction:</strong><br /> Lipoprotein(a) [Lp(a)] is a genetically regulated risk marker of atherosclerotic cardiovascular disease (ASCVD). Elevated Lp(a) levels have been linked to chronic kidney disease (CKD), potentially indicating impaired renal clearance and associated metabolic imbalances. This study aims to explore the relationship between Lp(a) levels and estimated glomerular filtration rate (eGFR), shedding light on its clinical relevance in renal function assessment.</span></span></span></p> <p style="text-align:start"><span style="font-size:12px"><span style="font-family:Arial,Helvetica,sans-serif"><span style="color:#000000"><strong>Methods:</strong><br /> This cross-sectional study included 301 patients recruited between May 2023 and October 2024. Plasma Lp(a) levels were categorized based on European Atherosclerosis Society thresholds: Lp(a)<75 nmol/L and Lp(a)>100 nmol/L. eGFR was calculated using the Cockcroft-Gault equation. Correlations between Lp(a) and eGFR were assessed using Spearman’s rank coefficient, with p<0.05 considered statistically significant.</span></span></span></p> <p style="text-align:start"><span style="font-size:12px"><span style="font-family:Arial,Helvetica,sans-serif"><span style="color:#000000"><strong>Results:</strong><br /> The mean age of the cohort was 63±1 years, with 79.1% male. Comorbidities included hypertension (65.1%), dyslipidemia (64.8%), and diabetes (24.6%). Median Lp(a) levels were 65 nmol/L (IQR: 22–180 nmol/L), and mean eGFR was 83±2 mL/min/1.73m². A significant inverse correlation was observed between Lp(a) and eGFR (r=-0.112, p=0.027). Patients with Lp(a)>100 nmol/L had lower mean eGFR (77±3 mL/min/1.73m²) compared to those with Lp(a)<75 nmol/L (85±3 mL/min/1.73m²; p=0.033). An incremental rise in Lp(a) levels with declining eGFR was noted across CKD stages, although significance in advanced stages was limited by small sample sizes.</span></span></span></p> <p style="text-align:start"><span style="font-size:12px"><span style="font-family:Arial,Helvetica,sans-serif"><span style="color:#000000"><strong>Conclusion:</strong><br /> Elevated Lp(a) levels were associated with reduced eGFR. While cross-sectional data limit causal inference, Lp(a) may contribute for the increased risk of ASCVD in patients with renal impairment. Future longitudinal studies are warranted to confirm these findings and explore therapeutic strategies targeting Lp(a).</span></span></span></p> <p style="text-align:start"> </p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site